Evaxion significantly expands vaccine development collaboration with MSD
26. September 2024 07:30 ET
|
Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29. Mai 2024 02:00 ET
|
Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
05. April 2023 07:00 ET
|
Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16. März 2021 08:00 ET
|
Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
Immutep Expands Part B of TACTI-002 Study
05. März 2021 08:00 ET
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians
07. Dezember 2017 09:37 ET
|
HealthEC
NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet), a wholly-owned subsidiary of the Medical Society of Delaware...